Proventys has developed novel, web-based products incorporating evidence-based guidelines, predictive technologies, and other information to address the complexity of clinical decision-making and improve patient outcomes. These solutions uniquely engage and serve the needs of patients, providers, and payers alike, offering effective tools to enhance the quality of care, while taking on medical cost containment challenges.

The application of smart technology and more personalized and predictive approaches to care is critical to improving clinical decision-making and engaging payers to capture value.

Proventys CDS™

Proventys has developed a first-of-its kind clinical decision support platform that dynamically presents practice guidelines, primary evidence, and other key information to help clinicians optimize treatment decisions for patients on a personalized basis. Focused first in oncology, Proventys CDS can serve as a practical decision-making tool for clinicians in multiple medical specialties.

• Proventys CDS Oncology™ powered by NCCN^®   – Through an exclusive collaboration with the National Comprehensive Cancer Network^® (NCCN^®), Proventys has developed a highly differentiated clinical decision support platform that allows clinicians to integrate current evidence into their practice more easily, and apply real-time information to guide diagnostic and therapeutic decisions for their patients. In parallel, Proventys has launched the AlignQI™ pathways program, a quality-focused offering designed to bridge the interests of payers and providers through increased concordance to evidence-based standards and streamlined administrative processes.

Proventys PDx™

At certain points along given care pathways, clinicians face complex decisions where there are significant clinical and economic outcomes at stake. To help clinicians process the volume of clinical, genomic, and other patient-specific data more effectively, Proventys is developing a portfolio of software-based predictive tests that quantify a patient’s individualized risk for an outcome of interest (adverse event, response to therapy, recurrence of disease) and guide appropriate treatment decisions.

• Proventys PDx Oncology™ and the FN PDx™ – The company’s lead predictive test, delivered through Proventys PDx Oncology, is designed to assess an adult cancer patient’s risk of developing chemotherapy-induced febrile neutropenia (FN), a costly, serious adverse event caused by the toxic effects of chemotherapy. The FN PDx uses a validated, multivariate statistical model to calculate a patient's numerical risk of developing FN during the first four cycles of chemotherapy. Results from each risk assessment are presented to the clinician along with published clinical guidelines to help determine if prophylactic treatment with colony stimulating factor is appropriate for each specific patient.
  
  Under review by the FDA (de novo); not available for sale in the United States.